Pluri Inc. (PLUR)
NASDAQ: PLUR · Real-Time Price · USD
1.810
+0.070 (4.02%)
At close: Aug 6, 2026, 4:00 PM EDT
1.810
0.00 (0.00%)
Pre-market: Aug 7, 2026, 7:13 AM EDT
Pluri Employees
As of June 30, 2025, Pluri had 142 total employees, including 127 full-time and 15 part-time employees. The number of employees increased by 24 or 20.34% compared to the previous year.
Employees
142
Change (1Y)
24
Growth (1Y)
20.34%
Revenue / Employee
$7,599
Profits / Employee
-$179,852
Market Cap
19.53M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 142 | 24 | 20.34% | 127 | 15 |
| Jun 30, 2024 | 118 | -16 | -11.94% | 106 | 12 |
| Jun 30, 2023 | 134 | -25 | -15.72% | 123 | 11 |
| Jun 30, 2022 | 159 | -3 | -1.85% | 154 | 5 |
| Jun 30, 2021 | 162 | 4 | 2.53% | 153 | 9 |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Palatin Technologies | 29 |
| Passage Bio | 24 |
| Citius Pharmaceuticals | 23 |
| OSR Health | 22 |
| Jasper Therapeutics | 22 |
| NeuroSense Therapeutics | 17 |
| Lipocine | 14 |
| Pasithea Therapeutics | 5 |
PLUR News
- 9 days ago - Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK - GlobeNewsWire
- 24 days ago - Pluri announces chairman Alejandro Weinstein ownership surpasses 30% - TheFly
- 7 weeks ago - Plurilock Announces Results of Annual General Meeting - Newsfile Corp
- 2 months ago - Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing - GlobeNewsWire
- 4 months ago - Pluri announces additional $2.5M investment from Alejandro Weinstein - TheFly
- 6 months ago - Pluri secures global IP position with CNIPA for immune cell expansion - TheFly
- 7 months ago - Pluri completes first phase of program with Resbiomed Technologies OOD - TheFly
- 8 months ago - Pluri announces expansion of manufacturing agreement with Remedy Cell - TheFly